LightDeck Diagnostics, formerly MBio Diagnostics, is the innovator of the proprietary LightDeck® platform that delivers highly sensitive, lab-quality results in minutes, virtually anywhere. We are developing a robust portfolio of human diagnostic tests internally and collaborate with commercial, academic and government partners.
Our team consists of industry veterans, engineers and scientists with expertise in hardware and software development, assay development and manufacturing. Our facilities in Boulder, Colorado include fully equipped biosafety laboratories for assay development and controlled manufacturing for cartridge production.
We are developing a portfolio of diagnostic tests for settings where lab-quality results are vital in making time-critical decisions.
The LightDeck COVID-19 Total Antibody Test helps to determine if a person had a past or recent infection.
This product line includes point-of-care tests to assess heart attack, heart failure or blood clots in the lungs.
Our commercial collaborations are matched to the partner’s needs. We provide engineering and assay development expertise, including migrating existing assays to the LightDeck platform and developing novel assays. Contact us to explore partnership opportunities.
LightDeck Diagnostics collaborate with government agencies, including BARDA, DARPA, NIH, NOAA, NSF and others, on product development in COVID-19, host-response, sepsis and water testing.
Quality Management System
Our Quality Management System is certified to ISO 13485:2016. Medical devices companies must demonstrate that they consistently meet customer and applicable regulatory requirements to meet this rigorous standard.